AZD-8309

Research use only, not for human use.

AZD-8309 (AZD8309) is a potent and orally bioavailable CXCR2 antagonist.

AZD-8309 (AZD8309) is a potent and orally bioavailable CXCR2 antagonist that has been proposed to regulate the transmigration of neutrophils; significantly reduces MPO in the pancreas and lungs, and reduces intrapancreatic trypsin and elastase activity in caerulein-pancreatitis; also reduces cathepsin B activity and MPO in taurocholate-pancreatitis; also antagonises the CCR2b receptor but it is 10-fold less potent than at CXCR2.COPD Phase 1 Clinical.

——

Animal Model:Male C57BL6 mice (25-30 g) with experimental pancreatitis Dosage:50 mg/kg Administration:Oral gavage; twice daily starting 3 h prior to pancreatitis induction Result:Significantly reduced MPO in the pancreas and lungs (8 h & 24 h) and reduced intrapancreatic trypsin and elastase activity (8 h) in caerulein-pancreatitis.Reduced serum cytokine levels as well as histopathological damage.

AZD8309

GPCR/G Protein

Chemokine Receptor

Chemokine Receptor

Inflammation/Immunology

COPD

333742-48-6

384.42

C15H14F2N4O2S2

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (130.07 mM)

O=C1SC2=C(N[C@H](C)CO)N=C(SCC3=CC=CC(F)=C3F)N=C2N1

(R)-5-((2,3-difluorobenzyl)thio)-7-((1-hydroxypropan-2-yl)amino)thiazolo[4,5-d]pyrimidin-2(3H)-one

(-20℃)

With Ice Pack

≥ 2 years